Request Demo
Recent blog posts
Latest Hotspot
8 min read
Glecirasib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Glecirasib is a Small molecule drug targeting KRAS G12C, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Exagamglogene Autotemcel Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Exagamglogene Autotemcel is a CRISPR/Cas9 targeting BCL11A, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Ticagrelor Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Ticagrelor is a Small molecule drug targeting P2Y12 receptor, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Aducanumab-avwa Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Aducanumab-avwa is a Monoclonal antibody targeting APP, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Faricimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Faricimab is a Bispecific antibody targeting Ang2 x VEGF-A, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Gedatolisib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Gedatolisib is a Small molecule drug targeting Akt x PI3Ks x mTORC1 x mTORC2, at NDA/BLA. This 2026 report reviews clinical evidence, IP, deals, risks.
Latest Hotspot
8 min read
Lumateperone Tosylate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Lumateperone Tosylate: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Ambrisentan Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Ambrisentan is a Small molecule drug targeting ETA, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Riociguat Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Riociguat is a Small molecule drug targeting sGC, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Volanesorsen Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Volanesorsen is a ASO targeting APOC3, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.
Latest Hotspot
8 min read
Ensartinib Hydrochloride Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Ensartinib Hydrochloride is a Small molecule drug targeting ALK x ROS1 x c-Met, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks.
Latest Hotspot
8 min read
Cobimetinib Fumarate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 July 2026
Cobimetinib Fumarate: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.